3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
1
Amyloid Neuropathies, Familial
1
Interventions
pembrolizumab
610
Carboplatin
375
Paclitaxel
283
Cisplatin
268
Gemcitabine
256
Pemetrexed
194
Bevacizumab
191
Nivolumab
190
Docetaxel
190
Injections
169
Cyclophosphamide
148
atezolizumab
138
Capecitabine
134
Fluorouracil
133
Oxaliplatin
132
Dexamethasone
129
Fulvestrant
115
durvalumab
114
130-nm albumin-bound paclitaxel
111
fludarabine
102
Cetuximab
101
Leucovorin
97
Rituximab
96
venetoclax
90
Lenalidomide
84
Prednisone
79
enzalutamide
78
Azacitidine
76
Irinotecan
74
Ipilimumab
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
1 year
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled